<DOC>
	<DOCNO>NCT01861522</DOCNO>
	<brief_summary>The objective study : confirm superiority TAU-284 placebo two week administration pediatric patient perennial allergic rhinitis investigate safety TAU-284 .</brief_summary>
	<brief_title>The Confirmatory Study TAU-284 Pediatric Patients With Perennial Allergic Rhinitis</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , 2-arm parallel-group comparative study confirm superiority TAU-284 placebo two week administration TAU-284 ( 20 mg/day ) placebo pediatric patient perennial allergic rhinitis , `` change baseline total nasal symptom score ( total score three major nasal symptom [ sneeze , rhinorrhea , nasal congestion ] ) '' primary endpoint ; investigate safety TAU-284 .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<criteria>Patients age 7 15 year Patients receive diagnosis perennial allergic rhinitis accord diagnostic criterion Patients mean rhinorrhea score mean sneeze score least 2 basis symptom record nasal allergy diary observation period etc . Patients vasomotor rhinitis eosinophilic rhinitis Patients concurrent nasal disease may affect efficacy TAU284 Patients history nasal surgical procedure Patients positive result pollen antigen disperse study period Patients positive result dog dander cat dander antigen chance touch dog cat . Patients current previous history drug allergy Patients concurrently renal function abnormality may cause safety problem etc .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>TAU-284</keyword>
	<keyword>Bepotastine besilate</keyword>
	<keyword>Histamine H1 receptor antagonist</keyword>
	<keyword>child</keyword>
</DOC>